Inhibrx, Inc.
DelistedCIK 1739614fmd_0M7Q5WJ1Q20KMTN8FEE65AST3NManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Mar 31, 2024, 21 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Total revenues | 13 | 13 | 7 | 2 | 2 |
| Research and development | 48 | 73 | 71 | 110 | 192 |
| Total operating expenses | 57 | 80 | 84 | 131 | 221 |
| Operating income | (44) | (67) | (77) | (129) | (219) |
| Other non-operating income (expense) | (7) | (8) | (5) | (16) | (21) |
| Income before taxes | (51) | (76) | (82) | (145) | (240) |
| Income tax expense | 1 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (51) | (76) | (82) | (145) | (240) |
| Net income | (51) | (76) | (82) | (145) | (241) |